HART News Alert Harvard Apparatus Regenerative (HART) 3.10 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Harvard Apparatus Regenerative (HART) 3.10 $HART

Harvard Apparatus Regenerative Technology Schedules Investor Teleconference for December 23, 2014, at 11:00 A.M. ET
Business Wire - Mon Dec 22, 1:19PM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ: HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, will hold a conference call to discuss recent events at 11:00 AM (Eastern Time) on December 23, 2014. On that call, management may take questions from the audience on any of a number of topics related to the business, including operations, plans and outlook.
HART: 3.10 (-0.05)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 11:49AM CST

MPET: 0.92 (+0.02), EOPN: 9.37 (-0.02), AVAV: 27.39 (-0.11), NRX: 4.67 (+0.03), VSR: 3.01 (-0.03), MCOX: 3.11 (-0.01), SDRL: 11.90 (+0.04), NADL: 1.68 (-0.08), PDII: 1.63 (-0.01), CUB: 53.41 (-0.09), HKTV: 9.20 (+0.01), SOL: 1.48 (+0.03), VEEV: 26.88 (+0.25), DO: 38.66 (-0.62), IDRA: 3.89 (+0.02), TITN: 13.96 (-0.31), VGGL: 2.89 (+0.04), HART: 3.10 (-0.05), LIQD: 0.40 (-0.34), CTRP: 45.00 (-0.12)

Harvard Apparatus backs out of Russia
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 7:23AM CST

HART: 3.10 (-0.05)

Harvard Apparatus Regenerative Technology No Longer Supporting Studies in Russia; Will Continue Focus on Preclinical Processes in the U.S. and EU
Business Wire - Wed Nov 26, 6:30AM CST
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), or HART, a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea announced that it will no longer be providing its HART-Trachea product for future transplant procedures performed at Krasnodar, Russia as part of the ongoing airway transplant studies there. HART will continue to focus primarily on completing preclinical work necessary to initiate clinical trials for its HART-Trachea product in the EU and U.S. It has made recent progress in the U.S. and EU, including the granting of orphan designation by the U.S. Food and Drug Administration (FDA) and a productive meeting with the Medicines and Healthcare Products Regulatory Agency of the U.K. (MHRA, the equivalent of the FDA in the U.K.). HART anticipates that during 2015 it will file its Investigational New Drug application to initiate a U.S. clinical trial and a Clinical Trial Authorization application to initiate an EU clinical trial.
HART: 3.10 (-0.05)

I'm Selling Harvard Apparatus Regenerative Technology
Jim Royal, The Motley Fool - Motley Fool - Tue Nov 18, 8:27AM CST
It's time to sell Harvard Apparatus Regenerative Technology . My Special Situations portfolio acquired shares in the speculative research and development company before it was spun off from Harvard Bioscience   last year. Why sell? In...
HBIO: 5.15 (-0.09), HART: 3.10 (-0.05)

Harvard Apparatus Regenerative Technology misses by $0.01
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 6:46AM CST

HART: 3.10 (-0.05)

Harvard Apparatus Regenerative Technology Reports Operating Results for the Third Quarter Ended September 30, 2014
Business Wire - Thu Nov 06, 6:01AM CST
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq:HART), or HART, a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, reports unaudited financial results for the three and nine months ended September 30, 2014.
HART: 3.10 (-0.05)

The Company That Can Grow You A New Organ: A Promising Long-Term Investment
Daniel Kohlsdorf - Seeking Alpha - Thu Oct 30, 10:37AM CDT
About the company and its opportunities Harvard Apparatus Regenerative Technology (NASDAQ: HART ) makes the equipment used to create a new human trachea (breathing pipe) using the patient's own bone marrow cells. People who currently need a...
HBIO: 5.15 (-0.09), HART: 3.10 (-0.05)

HART reports November 6
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 11:01AM CDT

HART: 3.10 (-0.05)

Harvard Apparatus Regenerative Technology Schedules Release of Third Quarter 2014 Financial Results and Investor Teleconference for November 6, 2014
Business Wire - Mon Oct 27, 6:00AM CDT
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, will announce results of its third quarter ended September 30, 2014 before market trading hours on Thursday, November 6, 2014. A conference call to discuss the company's third quarter results and the company's operations is scheduled for that same day at 11:00 AM (Eastern Time). On that call, management may take questions from the audience on any of a number of topics related to the business, including operations, plans and outlook.
HART: 3.10 (-0.05)

Harvard Apparatus Regenerative Technology Updates Patient Status
Business Wire - Fri Oct 17, 7:30AM CDT
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq:HART), or HART, a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, has recently been informed by the principal investigator in the Russian regenerated trachea transplant studies in which it is taking part that one of the patients in that study has recently passed away. The Company has not been informed of the cause of death. The patient survived more than two years from the initial regenerated trachea transplant surgery that took place in 2012. Prior to that surgery, the patient had suffered several instances of life threatening respiratory failure and infections. The patient was indicated for the initial transplant surgery because there was both a progression of the respiratory failure and traditional tracheal surgery was impossible.
HART: 3.10 (-0.05)

Harvard Apparatus Regenerative Technology Obtains Orphan Drug Designation from U.S. Food and Drug Administration for HART-Trachea
Business Wire - Fri Sep 05, 1:51PM CDT
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), or HART, a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the HART-Trachea, which is intended to replace or repair a trachea that has been severely damaged by either trachea cancer or physical trauma.
HART: 3.10 (-0.05)

Harvard Apparatus Regenerative Technology Reports Operating Results for Second Quarter Ended June 30, 2014
Business Wire - Fri Aug 08, 6:00AM CDT
Harvard Apparatus Regenerative Technology, Inc. (Nasdaq:HART), or HART, a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, reports unaudited financial results for the three and six months ended June 30, 2014.
HART: 3.10 (-0.05)

Harvard Apparatus Regenerative Technology Schedules Release of Second Quarter 2014 Financial Results and Investor Teleconference for August 8th
Business Wire - Fri Aug 01, 3:00PM CDT
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, will announce results of its second quarter ended June 30, 2014 before market trading hours on Friday, August 8, 2014. A conference call to discuss the company's second quarter results and the company's operations is scheduled for that same day at 11:00 AM (Eastern Time). On that call, management may take questions from the audience on any of a number of topics related to the business, including operations, plans and outlook.
HART: 3.10 (-0.05)

Harvard Apparatus Regenerative Technology's HART-Trachea Spotlighted in NBC-TV News Special on June 27
Business Wire - Mon Jun 30, 6:30AM CDT
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, announces its HART-Trachea was spotlighted in a two-hour-long NBC-TV News Special on Friday, June 27.
HART: 3.10 (-0.05)

Harvard Apparatus Regenerative Technology Collaboration with Texas Heart Institute Profiled by Houston's NBC-TV Affiliate on February 19
Business Wire - Wed Feb 26, 6:00AM CST
Harvard Apparatus Regenerative Technology, Inc. (NASDAQ:HART), a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, was featured February 19 in a television segment and article reported by the NBC-TV affiliate in Houston (KPRC-TV).
HART: 3.10 (-0.05)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 278

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Engrain's Geospatial Innovation Pushes Property Mapping Forward

Updated Category News Views 94

Pushing the Boundaries of Property Mapping How far can you expand the boundaries of property mapping tech? Well, Engrain seems hell-bent on finding out by cranking their innovations up a notch. The Denver-based stalwart in interactive mapping is rolling out some mind-boggling enhancements that could redefine how the multifamily housing sector operates. This isn't just...

Continue Reading
Pine Tree Bets Big on Tulsa Hills Shopping Center

Updated Category News Views 132

Pine Tree's Latest Move in Retail Real Estate Ya ever watch a company make a move so aligned with its playbook that it feels like a script straight outta the boardroom? That's Pine Tree with its recent snag of Tulsa Hills Shopping Center for a cool $108 million. This ain't just any retail spot; it's a bustling hub nestled within the posh outskirts of Jenks, Oklahoma....

Continue Reading
TOYO Slips on Earnings Amid Strategic Expansion

Updated Category News Views 206

TOYO's Solar Journey: Ups and Downs If there's one thing riding high on volatility these days, it's solar energy. TOYO Co., Ltd. (Nasdaq: TOYO) spilled the beans on Q3 2026, and oh boy, it's a mixed bag. Revenue Jumps, Yet Profitability Takes a Hit Let's cut to the chase: the third quarter served up a 4.8% dip in revenue year-over-year, landing at $129 million, though it...

Continue Reading
Intel Hit by Securities Law Suit Amid PC Market Struggles

Updated Category News Views 69

Intel Faces the Music: Legal Battles Unfold So it seems Intel's got itself in a kettle of fish. The tech giant is being dragged into a courtroom dance, courtesy of a class action lawsuit led by DJS Law Group. Shareholders who snapped up Intel shares between July 23 and October 29, 2026, might be scratching their heads, wondering if they bought into a bit of a mirage. A...

Continue Reading
AvidXchange Acquisition Faces Fairness Investigation

Updated Category News Views 31

Unpacking the AvidXchange Turmoil Staring at the ticker tape feels like watching a drama unfold, and today it's all about AvidXchange Holdings, Inc. (NASDAQ: AVDX). Levi & Korsinsky, LLP has launched an investigation into the fairness of its acquisition, and let me tell you, when the suits start poking around, it means someone smells a rat. The deal in question? A buyout...

Continue Reading
Panduit's AI Cooling Lab Boosts Data Center Innovation

Updated Category News Views 21

Innovation in Cooling: Panduit's Latest Move You hear "AI" and "data center" together and you know it's not gonna be business as usual. Here's Panduit throwing another log on the fire with their newly minted AI Cooling Lab. Panduit's a big cheese in the electrical and network infrastructure world. They've taken their Thermal Lab, given it a face-lift, and now, they’re...

Continue Reading
Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 213

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
Quantum X and Everest Cloud Partner in South Asia Push

Updated Category News Views 42

An Unlikely Alliance for Cutting-Edge Tech You gotta admit, the fusion of a U.S.-based tech outfit with a Nepalese cloud provider wasn't the market move anyone saw coming. But here we are—Quantum X is hitching its quantum computing dreams to Everest Cloud's solid local foothold across six South Asian markets. We're talking Nepal, India, Bangladesh, Bhutan, Sri Lanka,...

Continue Reading
DHL Leverages Robust Growth in Resilient Supply Chains

Updated Category News Views 31

Supply Chain Resilience: A Strategic Game Changer Market volatility's got its teeth in the game, and everyone in logistics knows it. DHL Supply Chain isn't just sitting back; they're riding the wave of change, snagging a 12% revenue bump in 2026. It's not your typical headline growth, either. More like the kind of growth that gets logistics gurus eyeing those contract...

Continue Reading

Top 5 Most Recently Viewed Articles

Analysts Adjust Forecasts for Ford Motor Company Ahead of Q3 Earnings

Updated Category News Views 244

Ford Motor Company Set to Announce Q3 Earnings Results Ford Motor Company (NYSE:F) is preparing to release its earnings results for the third quarter shortly. Investors and market analysts are keeping a close eye on what the iconic American automotive manufacturer will report. Analysts' Earnings Expectations Current expectations from analysts suggest that Ford is likely...

Continue Reading
Erithmitic Inc. Unveils Navigate Re: A New Era in Investment

Updated Category News Views 168

Erithmitic Inc. Introduces Navigate Re Limited Erithmitic Inc., a forward-thinking alternative asset manager, has recently made waves in the financial sector by introducing its new reinsurance entity, Navigate Re Limited. This strategic initiative reflects the company’s commitment to enhance its investment capabilities while laying the groundwork for significant future...

Continue Reading
Torres Trade Law Earns Prestigious Recognition in Rankings

Updated Category News Views 141

Celebrating Outstanding Achievements in Trade Law Torres Trade Law, PLLC, renowned for its commitment to international trade law, has made headlines following its recent recognition from the esteemed Chambers and Partners. The firm is thrilled to announce that its Founder and Managing Member, Olga Torres, has been nationally ranked for her outstanding work in the field of...

Continue Reading
Prudent Growth Partners Achieves Success with Town Center Sale

Updated Category News Views 163

Prudent Growth Partners Completes Successful Sale Prudent Growth Partners, LLC, a leading private equity real estate firm, recently announced the completion of the sale of Rolesville Town Center, marking an exceptional achievement for the company. The property was sold for $4.5 million, reflecting a strategic financial decision that continues to highlight the firm’s...

Continue Reading
Emerging Trends and Market Insights in Industrial Recycling Services

Updated Category News Views 162

Growth of Industrial Packaging Recycling Services The industrial packaging recycling services market is on a dynamic growth trajectory, boosting its size from USD 67.76 billion and aiming to reach USD 100.65 billion within a decade. This rapid expansion highlights a significant global trend towards eco-friendly solutions in packaging and waste management, emphasizing...

Continue Reading